0000000000318863

AUTHOR

Luca Moderato

showing 3 related works from this author

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-AR…

2021

Abstract Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry (DISCOVER)-ARNI] investigated whether sacubitril/valsartan in addition to optimal medical therapy (OMT) could reduce the rate of implantable cardioverter-defibrillator (ICD) indications for primary prevention in heart failure with reduced ejection fraction (HFrEF) according to European guidelines indications, and its potential predictors. Methods and results In this observational study, consecutive patients with HFrEF eligible for sacubitril/valsartan from 13 Italian centres were included. Lack o…

Left ventricular strainHeart failure; Implantable cardioverter-defibrillator; Left ventricular strain; Remodelling; Sacubitril/valsartanRemodellingHeart failureSacubitril/valsartanHeart failure Implantable cardioverter-defibrillator Left ventricular strain Remodelling Sacubitril/valsartanImplantable cardioverter-defibrillator
researchProduct

Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study

2021

Abstract Background COVID-19 has challenged the health system organization requiring a fast reorganization of diagnostic/therapeutic pathways for patients affected by time-dependent diseases such as acute coronary syndromes (ACS). Aim To describe ACS hospitalizations, management, and complication rate before and after the COVID-19 pandemic was declared. Design Ecological retrospective study. Methods: We analyzed aggregated epidemiological data of all patients > 18 years old admitted for ACS in twenty-nine hub cardiac centers from 17 Countries across 4 continents, from December 1st, 2019 to April 15th, 2020. Data from December 2018 to April 2019 were used as historical period. Results…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Adolescent[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyRate ratio03 medical and health sciences0302 clinical medicineInternal medicinePandemicEpidemiologymedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromePandemicsRetrospective StudiesOriginal PaperFramingham Risk Scorebusiness.industrySARS-CoV-2COVID-19Retrospective cohort studyGeneral Medicinemedicine.diseaseConfidence intervalHospitalizationbusinessAcademicSubjects/MED00010
researchProduct

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry

2022

Aims: Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results: Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [= LV end-…

EchocardiographyUltrasoundRemodellingHeart failureSacubitril/valsartanBiomarkers Cardiovascular disease Echocardiography Heart failure Imaging Remodelling Sacubitril/valsartan Speckle tracking UltrasoundCardiology and Cardiovascular MedicineCardiovascular diseaseBiomarkers; Cardiovascular disease; Echocardiography; Heart failure; Imaging; Remodelling; Sacubitril/valsartan; Speckle tracking; Ultrasound.BiomarkersImagingSpeckle tracking
researchProduct